Stabilization period [Design Issues]

posted by Vismayi – India, 2023-06-26 21:55 (385 d 06:09 ago) – Posting: # 23614
Views: 1,657

Good morning to one and all,

This is regarding patient PK study, we have upcoming study.

Indication: Ovary cancer

In this study,we need to stabilize patients but for how many days neither it is mentioned in specific guidance nor product leaflet. So, what duration we should we consider for stabilization.

Beside,study product can be taken until patient tolerate as per leaflet.


If the disease pre-valence is less and this may lead to challenge in recruitment. So can we consider replicate design over conventional two-way.


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,101 posts in 4,857 threads, 1,644 registered users;
80 visitors (0 registered, 80 guests [including 7 identified bots]).
Forum time: 04:04 CEST (Europe/Vienna)

One can show the following: given any rule, however “fundamental”
or “necessary” for science, there are always circumstances
when it is advisable not only to ignore the rule,
but to adopt its opposite.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5